Trial Is Assessing KRd Versus KCd in Newly Diagnosed MM Pts

Chicago—As an induction therapy in newly diagnosed, relatively young patients with multiple myeloma (MM), carfilzomib (Kyprolis, Amgen) with lenalidomide (Revlimid, Celgene) and dexamethasone (KRd) may have advantages over the combination of carfilzomib, cyclophosphamide and dexamethasone (KCd), according to initial results from an ambitious multicenter trial. In this study, KRd induction was slightly less well tolerated and performed less well for stem cell mobilization, but it achieved